Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Tirzepatide (Mounjaro), a dual GLP-1/GIP receptor agonist, received UK approval for type 2 diabetes and is under evaluation for obesity treatment
Zepbound (Branded - Limited Availability): Per Omzo's Terms, initial Zepbound consultation and supply is priced at $1,399/month, with follow-up consultations at the same rate
Venlo, Netherlands) following manufacturers instructions
Tirzepatide pairs GLP-1 with GIP receptor activation
Highlights of Prescribing Information: Rybelsus (semaglutide) tablet, for oral use
US$ 26.72
US$ 29.30
US$ 24.95
US$ 22.77
US$ 23.37
US$ 25.66
US$ 21.51
US$ 26.96
